JP2019518003A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518003A5
JP2019518003A5 JP2018555141A JP2018555141A JP2019518003A5 JP 2019518003 A5 JP2019518003 A5 JP 2019518003A5 JP 2018555141 A JP2018555141 A JP 2018555141A JP 2018555141 A JP2018555141 A JP 2018555141A JP 2019518003 A5 JP2019518003 A5 JP 2019518003A5
Authority
JP
Japan
Prior art keywords
composition
peptide
vectors
vector
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555141A
Other languages
English (en)
Japanese (ja)
Other versions
JP7163189B2 (ja
JP2019518003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/028755 external-priority patent/WO2017184933A1/en
Publication of JP2019518003A publication Critical patent/JP2019518003A/ja
Publication of JP2019518003A5 publication Critical patent/JP2019518003A5/ja
Priority to JP2022124716A priority Critical patent/JP2022169585A/ja
Application granted granted Critical
Publication of JP7163189B2 publication Critical patent/JP7163189B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555141A 2016-04-22 2017-04-21 インターロイキン10の抗炎症効果を亢進するための方法および組成物 Active JP7163189B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022124716A JP2022169585A (ja) 2016-04-22 2022-08-04 インターロイキン10の抗炎症効果を亢進するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326082P 2016-04-22 2016-04-22
US62/326,082 2016-04-22
PCT/US2017/028755 WO2017184933A1 (en) 2016-04-22 2017-04-21 Methods and compositions to enhance the anti-inflammatory effects of interleukin 10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022124716A Division JP2022169585A (ja) 2016-04-22 2022-08-04 インターロイキン10の抗炎症効果を亢進するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2019518003A JP2019518003A (ja) 2019-06-27
JP2019518003A5 true JP2019518003A5 (https=) 2020-05-14
JP7163189B2 JP7163189B2 (ja) 2022-10-31

Family

ID=60116475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555141A Active JP7163189B2 (ja) 2016-04-22 2017-04-21 インターロイキン10の抗炎症効果を亢進するための方法および組成物
JP2022124716A Pending JP2022169585A (ja) 2016-04-22 2022-08-04 インターロイキン10の抗炎症効果を亢進するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022124716A Pending JP2022169585A (ja) 2016-04-22 2022-08-04 インターロイキン10の抗炎症効果を亢進するための方法および組成物

Country Status (11)

Country Link
US (2) US20190112354A1 (https=)
EP (1) EP3445849B1 (https=)
JP (2) JP7163189B2 (https=)
KR (1) KR102430455B1 (https=)
CN (1) CN109477085B (https=)
AU (1) AU2017252327B2 (https=)
CA (1) CA3019846A1 (https=)
DK (1) DK3445849T3 (https=)
IL (1) IL262195B2 (https=)
RU (1) RU2731160C2 (https=)
WO (1) WO2017184933A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3369435T3 (pl) 2013-07-18 2020-04-30 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN112779285B (zh) * 2019-11-11 2023-01-06 百奥赛图(北京)医药科技股份有限公司 人源化il-10和il-10ra基因改造动物的构建方法和应用
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
KR102466921B1 (ko) * 2021-06-29 2022-11-14 주식회사 오에이티씨 인터루킨-4를 암호화하는 유전자를 포함하는 신경병증성 통증의 예방 또는 치료용 약학적 조성물
US20250051412A1 (en) * 2021-12-16 2025-02-13 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716804A (en) * 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2006130580A2 (en) * 2005-05-31 2006-12-07 Avigen, Inc. Mutant il-10
KR20130010121A (ko) * 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터,상기 벡터를 포함하는 숙주 세포 및 이의 용도
US9315825B2 (en) * 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US20150044281A1 (en) 2012-01-06 2015-02-12 The Regents Of The University Of Colorado, A Body Corporate Methods for the treatment of multiple sclerosis and other demyelinating disorders
PL3369435T3 (pl) * 2013-07-18 2020-04-30 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów

Similar Documents

Publication Publication Date Title
JP2019518003A5 (https=)
RU2018140988A (ru) Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10
JP7731579B2 (ja) 細胞並びにその使用方法及び製造方法
Ireland et al. Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10
Devarapu et al. Toll-like receptors in lupus nephritis
JP2019524721A5 (https=)
ES2684493T3 (es) Un polipéptido SAP para uso en el tratamiento de trastornos autoinmunitarios y enfermedad del injerto contra el huésped
Slade et al. Placenta-specific 8 limits IFNγ production by CD4 T cells in vitro and promotes establishment of influenza-specific CD8 T cells in vivo
US20220073585A1 (en) Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same
ES2908553T3 (es) Métodos para expandir una población de macrófagos alveolares en un cultivo de larga duración
RU2014132426A (ru) Частичные конструкты мнс и способы их применения
CN115135330A (zh) 修饰的干细胞及其使用方法
WO2022012531A1 (zh) 一种经修饰的免疫细胞的制备方法
JP2014523252A5 (https=)
Mondanelli et al. Islet antigen-pulsed dendritic cells expressing ectopic IL-35Ig protect nonobese diabetic mice from autoimmune diabetes
US20240150711A1 (en) Personalized redirection and reprogramming of t cells for precise targeting of tumors
CN101948544B (zh) FAT10基因siRNA重组模拟病毒及其制备方法和应用
WO2024059821A2 (en) Car t cell compositions for treatment of cancer
JP2023040034A (ja) 耐性を誘導するための操作された細胞
EP4188954A1 (en) Dual car-t cells
US20090060889A1 (en) Ii-RNAi involved Ii suppression in cancer immunotherapy
Horn et al. Gene therapy in the transplantation of allogeneic organs and stem cells
WO2025101276A1 (en) Compositions and methods for making and using immune cells
Yang et al. Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene
WO2015169994A1 (es) Composición capaz de modular la actividad de sidt1 para el tratamiento de enfermedades infecciosas inflamatorias o autoinmunes mediadas por ifn